Men diagnosed at this hospital trust can access the following services:

• Diagnostic Facilities:
• Multiparametric MRI
• Transperineal biopsy under general anaesthetic
• Transrectal ultrasound (TRUS) biopsy
• Choline PET
• PSMA (prostate-specific membrane antigen) PET scan
• Whole body MRI

• Treatment Facilities:
• Chemotherapy
• Joint specialist MDT clinic

• Support Service Facilities:
• Clinical Nurse Specialist (CNS) in all clinics
• Advanced PCa CNS
• Urology CNS
• Sexual function services

For Wales, this data completeness relates to patients diagnosed between April 2022 and March 2023.
For England, this data completeness relates to patients diagnosed in 2021. This is the data completeness of the National Cancer Registration Dataset (NCRD). For data completeness of the Rapid Cancer Registration Dataset (RCRD), please refer to the NPCA quarterly reports.

	Diagnosing Trust	Specialist MDT
No. of Cancer Registry records	202	1099
Performance Status recorded	96%	56%
PSA completed	15%	53%
Gleason Score completed	91%	86%
TNM completed	78%	70%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men with disease status determined	943	39897
Percentage of men diagnosed with metastatic disease	22%	17%

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

	Specialist MDT	National
No. of men diagnosed with low-risk localised disease	104	4684
Percentage of men with low-risk localised disease receiving radical treatment	3%	8%
No. of men diagnosed with locally advanced disease	308	15410
Percentage of men diagnosed with locally advanced disease receiving radical treatment	70%	68%